# Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

> **NCT04387084** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Southern California** · enrollment: 10 (actual)

## Conditions studied

- Advanced Malignant Skin Neoplasm
- Metastatic Malignant Skin Neoplasm

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Avelumab
- **BIOLOGICAL:** Cemiplimab
- **BIOLOGICAL:** Durvalumab
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Short-Term Fasting
- **BIOLOGICAL:** Dostarlimab
- **BIOLOGICAL:** Retifanlimab
- **BIOLOGICAL:** Toripalimab
- **BIOLOGICAL:** Tislelizumab

## Key facts

- **NCT ID:** NCT04387084
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-12
- **Primary completion:** 2026-08-12
- **Final completion:** 2027-08-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04387084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04387084, "Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04387084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*